

## REMARKS

Pursuant to 37 CFR 1.125(b), a substitute specification is hereby enclosed to make numerous typographical and grammatical errors noted by the Examiner. Also enclosed is a marked up copy of the substitute specification as required by 37 CFR 1.125(b)(2). Pursuant to 37 CFR 1.125(b)(1), Applicants hereby state that the substitute specification contains no new matter. The substitute specification also contains the amendments submitted with the response filed April 9, 2001 (mailed April 4, 2001), and entry is respectfully requested.

Claims 1 and 3 have been amended to recite "a set of oligopeptides", which is supported at least in the paragraph bridging pages 6 and 7 of the application; on page 7, lines 12-15; and on page 8, lines 11-14. The claims have also been amended to make stylistic changes, as requested by the Examiner and based upon suggestions from SPE A. Wang as discussed below, which do not alter the scope of the claims but rather are intended to utilize alternate language and formats to encompass the same subject matter. This includes a "spelling out" of the "scFv" abbreviation as well as a slight change in claim 3 to refer to the ability to distinguish as recited earlier in the claim. No change in claim scope is intended or believed to have occurred.

Claims 5-10 and 13-20 have been amended to begin with "The" in place of "A" as requested, and without altering the scope of the claims.

Claims 10 and 18 have been amended to present the same additional action using alternate language that refers back to the language of claims 1 and 3 from which claims 10 and 18 depend. Support is provided at least by the claims as originally presented and by page 26, lines 1-15 of the originally filed specification.

These amendments have been made for reasons related to business considerations and currently contemplated embodiments of the invention rather than in acquiescence to any position set forth in the Office Action. Applicants reserve the right to pursue the claims as previously filed in a continuing application.

No new matter has been introduced, and entry of the amendments is respectfully requested.

As an initial matter, Applicants and the undersigned thank Examiner Teresa Wessendorf and SPE Andrew Wang for the courtesy of a telephonic interview today, August 28, 2003

concerning the instant application. The undersigned provided the Examiners with a copy of proposed claim amendments as well as a copy of the Burnie et al. reference as cited in the Action prior to the interview.

The interview went through each of the issues raised in the Office Action mailed May 28, 2003, and while a number of the rejections were indicated as to be withdrawn by SPE Wang, a full response to each of the issues was still required. The following summarizes the undersigned's understanding concerning the status of particular rejections.

Rejection under 35 USC § 112, first paragraph (pages 3-5 of the Action): will be withdrawn.

Rejection under 35 USC § 112, second paragraph (pages 5-8 of the Action):

Subparagraph A): will be withdrawn in light of proposed claim amendments and upon presentation of evidence concerning difference between a single chain antibody fragment and "scFv";

Subparagraph B): Applicants should provide basis for "candidate";

Subparagraph C): will be withdrawn in light of proposed claim amendments;

Subparagraph D): will be withdrawn;

Subparagraph E): will be withdrawn;

Subparagraph F): Applicants should provide basis for relationship between "proteinaceous target" and "protein."

Rejection under 35 USC § 102, based on Barsomian et al. or Kruif et al. (pages 9-10 of the Action): will be withdrawn.

Rejection under 35 USC § 103(a), based on Barsomian et al. or Kruif et al., in the alternative, in view of Middeldorp et al. (pages 11-12 of the Action): will be withdrawn.

Rejection under 35 USC § 102 or alternatively 103(a) based on Burnie et al. (pages 12-13 of the Action): will be reconsidered in light of page 1603, right column and Applicant's belief that Burnie et al. only disclose the contacting of phage libraries with "peptide 1", "peptide 2", and "peptide 3" *individually*.

Turning in response to the Action, Applicants thank the Office for the withdrawal of the finality of the previous Office Action.

Objection to the specification

In light of the numerous typographical errors, many of which occur close together, Applicants have submitted a substitute specification pursuant to 37 CFR 1.125(b) as noted above. The substitute specification makes appropriate corrections for typographical and grammatical errors as noted by the Examiner.

Withdrawal of the objection to the specification is respectfully requested.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 1, 3, 5-10 and 13-20 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to be enabled by the specification. As noted above, SPE Wang indicated during the August 28, 2003 telephonic interview that this rejection would be withdrawn.

Nevertheless, Applicants traverse, however, because no *prima facie* case of non-enablement has been presented. While the statement of the rejection alleges that various terms in the claims are overly broad, Applicants respectfully submit that no case of undue experimentation to practice the claimed invention has been presented. To the contrary, and as previously submitted by Applicants, the skilled person would readily be aware of how to make and use the invention by displaying a multiplicity of antibody related peptides via replicable display packages, synthesizing more than one oligopeptide derived from a proteinaceous target on a solid phase, contacting the packages with the oligopeptides, and identifying or distinguishing peptides that bind to the oligopeptides from those that do not as encompassed by the claims and disclosed by the specification.

There is simply no basis for the allegation that the claims are only enabled for the particular antibodies and antigens provided in the Examples of the instant specification. Similarly, there is no basis for the allegation that the invention is no more than an invitation to experiment. While the invention may be used in the furtherance of experimentation by permitting the identification of antibody related peptides that bind a proteinaceous target of interest, this does not mean that it requires undue experimentation to make and use the invention.

To the contrary, and despite the characterization of the instant disclosure at pages 23 and 17 as limitations on the practice of the claimed invention, the specification, such as on pages 23 and 17, provide guidance for the practice of the invention.

Therefore, Applicants respectfully request that this rejection be withdrawn as indicated by SPE Wang.

Rejection under 35 U.S.C. § 112, second paragraph

Claims 1, 3, 5-10 and 13-20 were rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for reasons presented in subparagraphs A through F. As noted above, SPE Wang indicated during the August 28, 2003 telephonic interview that a number of the reasons in the subparagraphs of this rejection would be withdrawn. Nevertheless, Applicants traverse as follows.

Subparagraph A): The recitations of “proteinaceous target” and “peptide” are not unclear because it would be evident to the skilled artisan that the peptides are displayed on replicating packages while the proteinaceous target is the source from which oligopeptides will be derived and contacted with the displayed peptides.

Moreover, the actual acts of the methods as encompassed by claims 1 and 3 have been delineated by the use of alphabetical indicators. This should make it clear that the act of synthesizing oligopeptides (now “b”) and the act of identifying (now “d”) in claim 1) are unambiguously present in the claimed invention such that no essential acts have been omitted.

Furthermore, the recitation of “a set” in claims 1 and 3 emphasizes that a multiplicity of oligopeptides are to be synthesized and used in the practice of the invention. The alleged ambiguity concerning the length, number and kind of oligopeptides is misplaced because while the term oligopeptide is broad, there is no confusion as to what is meant by oligopeptide.

Applicants also respectfully submit that “the” surface of a replicable display package has antecedent bases from the recitation of “replicable display package”. Additionally, the term “capable” as used in the claims need not definitively identify a peptide as binding or not because it is the claimed invention which proceeds to identify a peptide as binding and thus within the

scope of “capable of binding”. Last, and with reference to attached Exhibit A (pages 96 and 97 from an immunology text), “scFv” as used in claim 1 refers to a single chain comprising a the V domains both a heavy and light chain linked by a synthetic peptide. This is in distinction to “single chain antibody fragment” as used in claim 1 is not limited to only the V domains of both a heavy and light chain. As indicated by the abstract by McGregor et al. (attached Exhibit B), a single chain antibody fragment they constructed contained the heavy and light chain V domain regions as well as the light chain kappa constant region. Therefore the two terms used in claim 1 are not co-extensive and can both be properly retained in the claim.

Subparagraph B): To the extent that the rejection of claim 3 is based on the points addressed above, Applicants rely on the discussion provided above with respect to claim 1. Additionally, Applicants point out that claim 3 is directed to distinguishing between peptides that bind from those that do not. It is this combination of peptides that is referred to as “candidate” peptides in the claim. Applicants respectfully submit that the skilled artisan would recognize this relationship between these terms and concepts in the claim and that no issue of indefiniteness is present.

Subparagraph C): Applicants refer to the amendments to claims 5-10 and 13-18 to recite “The” at the start of the claims.

Subparagraph D): Contrary to the statement of the rejection, claims 8 and 16 are directed to the narrower embodiment where the peptides of claims 1 and 3 (from which claims 8 and 16 depend, respectively) are single chain antibody fragments as opposed to other possible antibody related peptides.

Subparagraph E): Claims 10 and 18 have been amended to refer to the additional act that further defines the invention of claims 1 and 3 from which claims 10 and 18 depend, respectively. Because the language of claims 10 and 18 is referring to an additional act, the allegation that basis for the language must be present in claims 1 and 3 is misplaced.

Subparagraph F): Applicants refer to attached Exhibit C which contains the definition of “proteinaceous” from a medical dictionary. Page 1443 defines the term as “resembling a protein” as opposed to being only composed of protein in nature. Therefore, and in combination with the previously discussion in reference to page 7, lines 24-33 of the specification as originally filed, the term as used in the claims (proteinaceous target in claim 1 and proteinaceous antigen in claim 3) must refer to targets and antigens that either resemble a protein or are a protein in nature. Accordingly, claims 19 and 20, which clearly further define claims 1 and 3 respectively to be directed to targets and antigens that are proteins, are not indefinite.

#### Objection to the specification

With respect to the objection to the specification on page 8 of the Action, Applicants understand it to be based upon the lack of a literal disclosure of the method of claim 3 in the specification as originally filed. Applicants respectfully request that this objection be held in abeyance pending determination of the final language of claim 3 for possible incorporation into the specification if it is still deemed necessary.

In the event that incorporation of the language of claim 3 as originally filed is required, Applicants respectfully request that this requirement be clearly made so that an appropriate amendment to the specification may be made.

#### Prior art rejections under 35 U.S.C. § 102

Claims 1 and 3 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Barsomian (WO 95/15982). As noted above, SPE Wang indicated during the August 28, 2003 telephonic interview that this rejection would be withdrawn.

Nevertheless, Applicants traverse, however, because no *prima facie* case of anticipation has been presented for the reasons advanced previously. The statement of the rejection appears to correlate the use of a single target antigen, which may contain multiple oligopeptide epitopes, as equivalent to the use of a set of oligopeptides as encompassed by the instant claims.

Applicants respectfully submit that the two situations are completely distinct because the cited reference clearly does not teach the synthesis of oligopeptides as required by the claims. Therefore, no issue of anticipation is present.

Claims 1, 3, 5-10 and 13-20 were rejected under 35 U.S.C. § 102(b) as allegedly unpatentable over Kruif et al. As noted above, SPE Wang indicated during the August 28, 2003 telephonic interview that this rejection would be withdrawn.

Nevertheless, Applicants traverse, however, because no *prima facie* case of anticipation has been presented for the reasons advanced previously. The statement of the rejection appears to correlate the discussion of the possible use of portions of a molecule as equivalent to the use of a set of oligopeptides as encompassed by the instant claims. This is clearly incorrect because nowhere within the disclosure of the cited reference is there any indication of using the portions in the manner of a set of oligopeptides as encompassed by the present claims. Therefore, no issue of anticipation is present.

#### Prior art rejections under 35 U.S.C. § 103(a)

Claims 1, 3, 5-10 and 13-20 were rejected under 35 U.S.C. § 103(a) as allegedly unpatentable over Barsomian or Kruif et al. (in the alternative) in view of Middledorp et al. (USP 5,424,398). As noted above, SPE Wang indicated during the August 28, 2003 telephonic interview that this rejection would be withdrawn.

Nevertheless, Applicants traverse, however, because no *prima facie* case of obviousness has been presented. As an initial matter, Middledorp et al. do not cure the above-discussed deficiencies of either Barsomian or Kruif et al.. Moreover, no motivation to combine these disparate disclosures has been presented. Middledorp et al. do not discuss or suggest the use of replicable display packages to identify binding peptides and also do not discuss or suggest the use of multiple oligopeptides with such packages. Therefore, no issue of obviousness is present.

#### Prior art rejection under 35 U.S.C. § 102 or under 35 U.S.C. § 103(a) in the alternative

Claims 1, 3, 5-10 and 13-20 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Burnie et al. (abstract provided with the Action). Applicants have obtained a complete copy of Burnie et al. and it is attached as Exhibit D.

After a careful review of Burnie et al. and the statement of the rejection, Applicants respectfully traverse because no *prima facie* case of anticipation or obviousness has been presented.

Specifically, a review of the right columns on pages 1601 and 1603 of Burnie et al. indicates that contrary to the statement of the rejection, there was no disclosure of contacting antibody displaying phages with multiple oligopeptides from a single protein at the same time. To the contrary, the discussion on page 1603 clearly indicates that there was "panning" of the phage against each of the three peptides described on page 1601 individually. Accordingly, Burnie et al. cannot anticipate the instant claims.

Moreover, Burnie et al. appeared to be interested in the identification of antibodies that bind each of the epitopes represented by the three peptides. Therefore, there would have been no suggestion or motivation to contact the phage with all three peptides at the same time because it would then require extra effort to determine what phage binds which peptides. Accordingly, Burnie et al. present no issue of obviousness against the instant claims.

Accordingly, Applicants respectfully request that the instant rejection be withdrawn.

### CONCLUSION

In light of the above amendments and remarks, Applicants believe that the claims are in condition for allowance and urge passage of the application to issue. The Examiner is invited to contact Applicants' agent at the number listed below if it would be helpful in any way to resolve any remaining issues.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 313632000600. However,



the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: August 28, 2003

By: 

Kawai Lau, Ph.D.

Registration No. 44,461

Morrison & Foerster LLP


3811 Valley Centre Drive,

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5178

Facsimile: (858) 720-5125



"Marked-Up Copy"

TECH CENTER 1600/2300  
SEP 04 2003

RECEIVED

[TITLE:] METHODS AND MEANS FOR SELECTING PEPTIDES AND  
PROTEINS HAVING SPECIFIC AFFINITY FOR A TARGET

[0001] This invention relates to the field of proteinaceous biological molecules having  
5 specific affinity for a target. More specifically the invention relates to such molecules  
derived from specific binding peptides such as proteins or such as antibodies, in particular  
monoclonal antibodies or specific binding derivatives or fragments thereof. In an exemplary  
embodiment the invention relates to peptides and antibodies which are more or less  
randomly produced as large collections of different molecules (libraries) expressed on the  
10 surface of a replicable genetic package. From these libraries peptides or antibodies are  
affinity-selected for binding to the target molecule.

[0002] Specific binding affinities between biological molecules or derivatives thereof  
have been used throughout applied biotechnology, molecular biology, medical biology, etc.  
for a very long period of time for many different purposes. Some of the most commonly  
15 applied biological molecules having a specific binding affinity are antibodies. Antibodies  
are complex proteins usually composed of two light chains and two heavy chains which  
comprise constant regions and variable regions which variable regions again comprise  
hypervariable domains, which determine the binding specificity of the antibody  
(complementarity determining regions, (CDR)). Antibodies are part of the normal defense  
20 system of higher vertebrates. They are produced by cells of the immune system. Until 1975  
antibodies were obtained by administering an antigenic substance to an animal (often a  
rodent) and harvesting the antibodies produced by the animal in its immune response. This  
resulted in mixtures of antibodies having many different specificities for different binding  
sites on the antigenic substance. These mixtures are referred to as polyclonal antisera.

25 [0003] The advent of monoclonal antibodies (Kohler and Milstein (1975) Nature  
256:495) represented a significant technical breakthrough with important consequences both  
scientifically and commercially. Monoclonal antibodies are conventionally made by fusing  
antibody-secreting plasma cells from an immunized animal with a tumor cell line in order to  
immortalize the former plasma cells. The immortalized hybridomas are screened for the  
30 production of antibodies with the desired specificities. Selected hybridomas are expanded to  
large numbers and the monoclonal antibodies secreted into the medium are harvested and  
purified for application. Since the arrival of hybridoma technology, monoclonal antibodies  
have found broad application in procedures aimed at examining and identifying many

antigens in many formats from pregnancy tests to AIDS tests. They are also widely applied in research laboratories for use in studying and isolating a broad variety of molecules and for immunohistochemistry, i.e. identifying certain cells in tissues. For instance, monoclonal antibodies that are reactive with specific antigens expressed on subpopulations of cells can be utilized to detect these cells in tissue sections using immunohistochemical or immunofluorescent approaches. The inherent advantages of monoclonal compared to polyclonal antibodies is that they react only with one specific epitope and that they are standardized from batch to batch and from laboratory to laboratory.

[0004] Despite of all the advantages obtainable using monoclonal antibodies, there are a number of limitations associated with hybridoma technology and therefore with the monoclonal antibodies that can be obtained. For instance, the number of hybridomas that can be established and screened for the secretion of a certain antibody specificity is limited. The immunization protocol and the manner in which the animal's immune system handles the antigen favors the selection of hybridomas secreting antibodies against immunodominant epitopes, whereas other specificities will not be obtained because the immunizing antigen or some of its epitopes are not recognized by the animals immune system. In addition, the MoAbs obtained from animals are hardly suitable for therapeutical use in humans because they evoke an immune response. Some of these drawbacks may be circumvented by using antibody engineering, aiming at chimeric antibodies of which the variable regions are of animal origin and the constant regions are of human origin (the constant region is responsible for the bulk of the immune response). However these chimeras still evoke an immune response. Another possibility to avoid the immune response is a technique called CDR-grafting, whereby only the CDR's are of animal origin, which CDR's are inserted in a human antibody framework. These humanized antibodies are rather difficult to make and often ~~[lose]~~ lose some of their binding affinity.

[0005] Another way of modifying antibodies is by trying to obtain the smallest fragment that will still specifically bind the antigen (or to be more precise the epitope) with a significant affinity. The smaller the fragment, the less immunogenic it may be. This has resulted in Fab<sup>2</sup>, and Fab fragments, linked to peptide-like molecules comprising only one of the three CDR's present on each heavy and light chain of mammalian antibodies, i.e. CDR3 of the heavy chain.

[0006] In genetically engineering antibodies ways have also been found to avoid having to express at least two different subunits (a heavy and a light chain) for obtaining one antibody. This has been achieved by making a fusion through a peptide linker between a heavy and a light chain subunit. This results in so-called single chain antibodies, which will be discussed in more detail later on.

[0007] Apart from the drawbacks related to immunogenicity of monoclonal antibodies, there is also a limitation in the specificities obtainable with monoclonal antibodies. Nature employs a specific process in making CDR's of antibodies through a complex process of hypermutations, rearrangements and insertions in the gene fragment encoding the CDR, followed by a selection of antibody producing cells in primary and secondary lymphoid organs. The result of these processes is that the variety of binding specificities that can be produced in an animal is limited. As one result thereof monoclonal antibodies are not always useful in the application they are intended for, such as for example immunohistochemistry.

[0008] Immunohistochemical and immunofluorescent procedures involving tissue sections generally consist of the steps of embedding a tissue in an embedding medium, with or ~~[without]~~ without prior or subsequent fixation or freezing of the tissue, cutting the embedded tissue in thin sections, incubating the tissue sections with monoclonal antibodies, amplification of the signal and visualisation of cells that have bound antibody by an enzymatic reaction and precipitation of substrate or by fluorescent labels.

[0009] A drawback of conventional monoclonal antibodies is that they often do not bind to target epitopes in fixed tissue sections, presumably as a result of destruction of the target epitope by the fixation procedure. Fixation and embedding procedures such as paraffin embedding and formalin fixation, that are optimal for preservation of the anatomical structure of the tissue and are routinely used for medical diagnosis, lead to extensive protein denaturation thus limiting the application of monoclonal antibodies that often bind to native epitopes.

[0010] Another breakthrough in specific binding technology involves the use of replicable genetic display packages. The term replicable genetic display package or display package describes a biological particle which has genetic information providing the particle with the ability to replicate. The package can display a fusion protein including an antibody, ~~[antibody]~~ antibody fragment, protein or peptide. The fusion protein is presented by the

display [~~pac~~-kage] package in a context which permits the antibody to bind a target structure that is [~~contae~~-ted] contacted with the display package. The display package can be, for example, derived from bacterial cells, bacterial spores or bacterial [~~viruses~~] viruses. In phage display technology a gene fusion is made between a sequence encoding a peptide of interest and a sequence encoding a protein displayed on the outside of a phage (actually the peptide sequence is inserted in the protein's encoding sequence). Libraries of very large numbers of display packages containing all kinds of different peptides within one of their surface proteins can be easily produced and selected and tested based on their binding affinity for other molecules or cells, etc.

10 [0011] Parts of human antibody genes and sequences encoding single chain variable regions have been inserted in such phage genes and thus antibody fragment phage display libraries have been obtained. Display libraries of antibody variable regions may be constructed by a variety of methods. In general, a large collection of antibodies or antibody-fragments is expressed on the surface of a replicable genetic display package. In an  
15 exemplary embodiment of the present invention, the display package is a phage particle which comprises an antibody-coat protein fusion; the nucleotide sequences used for construction of the antibodies are of human origin. The library of surface expressed antibody molecules is brought into contact with the target antigen for affinity selection of antibodies that bind to the antigen. This procedure allows the rapid screening of very large  
20 collections of displayed antibody molecules, yields human antibodies and does not require immunization of an animal. Novel specificities may be obtained from such libraries.

[0012] Phages expressing antibody specificities of interest are selected from libraries in a four step procedure 1) affinity binding of phages to the target antigen, 2) removal of non-bound phages by washing 3) elution of bound phages and 4) infection and propagation of  
25 eluted phages in *E. coli* bacteria. A variety of targets has been successfully employed to obtain phage antibodies from libraries by affinity selection. Phage antibody affinity selections have been performed on purified antigens coated to a solid phase, on intact eukaryotic cells in suspension or in monolayers and on prokaryotic cells.

[0013] The language "affinity binding" and "affinity selection" as well as "differential  
30 binding" refer to the separation of members of the peptide or antibody display library based on the differing abilities of these molecules on the surface of each of the display packages of the library to bind to the target structure. Examples of affinity selection include affinity

chromatography, immunoprecipitation, fluorescence activated cell sorting, agglutination and plaque lifts.

[0014] In all phage antibody affinity selection procedures, it is imperative to obtain a large collection of binding phages in the first round of selection, preferably binding to diverse regions of the target. In subsequent rounds of selection, procedures may be implemented to select from this collection those antibodies that fulfill specific requirements.

[0015] The present invention provides further selection methods whereby novel specificities can be easily obtained and/or useful antibody fragments and epitopes (or even any combination of two peptides or proteinaceous substances having binding affinity for each other) can be identified and obtained.

[0016] In one embodiment the invention provides a method for identifying a peptide or antibody capable of specific binding to a proteinaceous target, comprising displaying the peptide or antibody on the surface of a replicable display package, synthesizing sets of oligopeptides derived from the proteinaceous target on a solid phase and contacting the specific binding peptide with the solid-phase-bound oligopeptide to allow for binding. The peptides expressed on the replicable display package may be linear or have another conformation as for example in di-sulfide bridged circular peptides or peptides that contain more than one disulfide bridge and have an ~~[unpredictable]~~ unpredictable conformation. In addition, the target oligopeptides may be linear or comprise another configuration.

[0017] Thus, the present invention provides a method that allows the directed pre-selection of phage antibodies (or other binding peptides) to defined sets of oligopeptides representing (sub)regions of the target molecule. For the purpose of the present invention, the term antibody in its various grammatical forms is art-recognized and includes immunoglobulin molecules and immunologically active portions and/or derivatives thereof, i.e. molecules that contain an antigen binding site. The peptides are synthesized in overlapping or non-overlapping sets of multimers on polystyrene rods or other solid phases such as membranes or beads. In the preferred embodiment, polystyrene rods used for pepscan technology are used. After selection on solid phase-bound rods, collections of phages enriched for anti-oligopeptide phage antibodies can be used in subsequent rounds to select anti-oligopeptide phages that also bind to the target molecule in a another configuration or to select antibodies that discriminate between various forms of the target proteinaceous substance. ~~[Many]~~ With many examples of anti-oligopeptide antibodies that

bind to the target protein, the oligopeptide is derived from ~~[have been]~~ the target protein as described in the scientific literature. Herein oligopeptides are defined as comprising 6-30, preferably 8-20 amino acid residues. They will also be simply referred to as peptides.

[0018] The term pepscan relates to a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides, essentially as described (Geysen H., et al., Proc. Natl. Acad. Sci. USA 81, 3998 (1984)). In the original procedure, the peptides are synthesized on polyethylene rods as solid support. Other solid supports such as membrane filters or beads may also be used. Various peptide formats may be synthesized including linear peptides and di-sulfide bridged circular peptides.

[0019] Thus, in one embodiment the present invention provides a method for generating antibodies specific for sets of peptides synthesized on a solid phase such as the polyethylene rods used in pepscan technology. The subject method generally comprises the steps of synthesizing on a solid phase sets of peptides spanning a target molecule or a subregion thereof; the construction of a display library of antibodies or peptides; the selection of displayed peptides or antibodies that bind to the solid-phase-bound peptides using affinity selection and affinity absorption techniques.

[0020] In exemplary embodiments, the display library of peptides or antibodies can be a phage display library or a display library generated on bacterial or yeast cell surface.

[0021] After one or multiple rounds of selection, the binding displayed antibodies or peptides may be subjected to additional rounds of selection on peptides or on the target protein in its native or denatured configuration. In exemplary embodiments, the subject method can be used to isolate anti-peptide antibodies that also bind to the target protein in its native configuration, for example a marker expressed on normal or malignant eukaryotic cells, or in denatured configuration such as markers expressed on cells in fixed tissue sections. Likewise, the subject method can be used to generate antibodies which can discriminate between a protein and other related forms of the protein, by using a subtractive approach. The related forms of the protein can differ by one or more amino acids from the target protein or differ as a result of posttranslational modifications such as glycosylation.

[0022] In an illustrative embodiment of the subject method, a specific antibody can be generated by affinity selection using a synthetic antibody phage display library. The phage library is incubated with the pepscan block containing rods covered with peptides spanning

the extracellular region of a transmembrane protein and phages are allowed to bind to individual rods. After removal of non-bound phages by washing, bound phages are eluted from the rods and propagated in bacterial cells. Multiple subsequent rounds of selection may be performed using the same approach. Alternatively, the binding phages from the first round of selection on solid phase-bound peptides may be selected for binding to the protein in another configuration such as that expressed on a cell or a recombinant protein. In the subtractive approach, phages eluted from the peptides in the first and/or subsequent round(s) of selection may be incubated with rods covered with other peptides, such as peptides differing one or more amino acids from the peptide used for the initial selection, in order to absorb phages that crossreact with related molecules.

[0023] It is contemplated that the present invention can be applied to obtain bi-specific antibodies that bind to two non-overlapping epitopes on the same molecule of ~~[mono-meric]~~ monomeric antigen. Such antibodies have been shown to have enhanced affinity due to the chelate effect (Cheong, H.S., et al. Biochem. Biophys. Res. Comm 173, 795 (1990)). The DNA encoding the pool of phage antibodies affinity selected for binding to a set of overlapping peptides may be recloned into vectors permitting the display of various formats of bi-specific antibodies. The displayed bi-specific antibodies may be affinity selected for binding to the target protein to obtain high affinity binding phages. Using the same strategy, bi-specific antibodies may be obtained that bind to two epitopes that are expressed on different molecules.

[0024] It is also contemplated by the present invention that individual antibodies or peptides, and the genes or oligonucleotides encoding these antibodies or peptides, can be isolated from the phage display library after affinity enrichment. These genes and oligonucleotides can be used for subcloning into expression vectors for production of antibodies and derivatives of the oligonucleotides can be used for nucleotide sequencing and the information used to produce chemically synthesized peptides or peptides produced by recombinant DNA methods such as production in prokaryotic or eukaryotic expression systems.

[0025] In an alternative embodiment, the present invention provides a method for identifying a peptide capable of specific binding to a fixated biological target, comprising displaying the peptide on the surface of a replicable display package and contacting said specific binding peptide with the fixated target to allow for binding.



[0026] Thus, the present invention provides a method that facilitates the selection of antibodies that are suitable for immunohistochemical and immunofluorescent procedures with tissue sections that have been embedded and fixed with a variety of procedures. In addition, the procedure facilitates the isolation of antibody specificities that bind to particular anatomical regions of a tissue section, for example a region infiltrated by tumor cells by using a subtraction procedure and/or micromanipulation of individual cells or small groups of cells. The method employs large libraries of antibodies or peptides expressed on the surface of a replicable display package. The display libraries may be constructed by a variety of methods. In an exemplary embodiment the display package is a phage particle which comprises an antibody-coat protein fusion; the nucleotide sequences used for construction of the antibodies are partially synthesized and assembled [~~in vitro~~] *in vitro*. These libraries contain many novel specificities, including antibodies against self antigens.

[0027] In the basic approach, phages expressing antibody specificities of interest are selected from this library in again a four step procedure 1) binding of phages to the embedded and fixed tissue sections, 2) removal of non-bound phages by washing 3) elution of bound phages and 4) infection and propagation of eluted phages in *E. coli* bacteria. To obtain specific phage antibodies that bind to a particular tissue or cell type, the method may be extended by absorbing eluted phage antibodies to remove unwanted specificities. This may be achieved by incubating eluted phage antibodies with sections of other tissues or with sections of the same tissue not containing the target cell of interest and subsequent propagation of unbound phages. In addition, to obtain phage antibodies specific for a particular cell type, for example defined by anatomical localization, individual or groups of cells or pieces of tissue and attached phages may be scraped from the tissue section by a micromanipulator.

[0028] The present invention makes available a powerful directed approach for isolating specific antibodies or peptides by antibody or peptide display technologies in combination with solid-phase-dependent peptide synthesis.

[0029] The present invention further makes available a powerful directed approach for isolating specific antibodies or peptides by antibody or peptide display technologies in combination with selection procedures on tissue sections or whole tissues.

[0030] In one exemplary embodiment of the present invention, the display package is a phage particle which comprises an antibody fusion coat protein that includes the amino acid

sequence of an antibody variable region. A library of replicable phage vectors, especially phagemids encoding a library of antibody fusion coat proteins is generated and used to infect suitable host cells. The antibody variable genes used to construct the phage library may be entirely derived from the lymphocytes of individuals or (partly) assembled [~~in-vitro~~]

5 ~~in vitro~~ as in semi-synthetic phage antibody display libraries. An important determinant of the composition and diversity of these [~~in-vitro~~] *in vitro* immune systems is the source of antibody genes used as building blocks to construct the library. Libraries may be assembled from the V regions expressed by the B lymphocytes of an individual known to have mounted a particular immune response as a result of immunization or exposure to an

10 infectious agent. The B cell repertoire in the lymphoid organs of these individuals is enriched for antigen-specific B cells and plasma cells that have undergone clonal expansion and antigen affinity maturation, thus increasing the likelihood of selecting high affinity antibody fragments from the eventual "immunized" phage library. Libraries may be constructed from the V regions expressed by the B cells of "non-immunized" individual in

15 an attempt to recruit all the diversity generated by the natural immune system. Importantly, it should be noted that the B lymphocytes of naive, immunized or infected individuals have been through positive and negative selection forces in primary and secondary lymphoid organs. The net effect of these processes is a B cell repertoire that is less diverse than potentially attainable, based on rearrangement of immunoglobulin gene segments, N region

20 insertions and somatic hypermutation. This *in vivo* antibody repertoire selection is mirrored in the eventual "naive" phage library. An alternative approach to create diverse libraries exploits the use of large collections of cloned V genes to which randomized CDR3 and JH regions are fused [~~in-vitro~~] *in vitro* by PCR. The diversity of these "semi-synthetic" libraries is not constrained by the forces of [~~selection~~] selection acting in the natural immune

25 system. It may be anticipated that such libraries contain specificities not present in the actual antibody repertoires of humans. In the exemplary embodiment a synthetic library is used because it is expected to contain the novel anti-peptide specificities to be selected.

[0031] Phage particles formed from the chimaeric protein can be separated by affinity selection based on the ability of the phage-associated antibody to bind to the target peptide

30 synthesized on rods of a pepscan block. The rods on the pepscan block are decorated with individual peptides, the amino acid sequence of which is determined by the amino acid sequence of the target protein. After one or multiple rounds of selection on peptides synthesized on the pepscan block, the phages are selected for binding to the target protein in

its native or denatured configuration. For example, the target protein may be a purified recombinant protein expressed in eukaryotic or prokaryotic cells, or a recombinant protein expressed on the cell surface of a prokaryotic or eukaryotic cell. Phages binding to the target protein are eluted, propagated and eventually analyzed for binding.

5     **[0032]** After one or multiple rounds of affinity selection on peptides, a subtractive or absorption step may be included to obtain phages that discriminate between two closely related peptides. For example, phages that discriminate between the closely related peptide ~~[repre-sented]~~ represented by the amino acid sequences DLVYKDPARPKI (SEQ ID NO:1) and DLVYKDPYRPKI (SEQ ID NO:2) may be obtained by affinity selection on the amino  
10    acid sequence DLVYKDPARPKI (SEQ ID NO:1), followed by absorption of phages binding to the amino acid sequence DLVYKDPYRPKI (SEQ ID NO:2). In the latter step, non-discriminative phages recognizing both peptides are removed and not used for propagation. Antibodies produced by this method can for example be used to distinguish various naturally occurring isoforms of a protein or for immunochemical assays for detecting  
15    cell transformations arising due to mutation of an oncogene or an anti-oncogene.

**[0033]** The terms absorption and subtraction refer to the removal of phage antibodies with unwanted specificities from a collection of phages obtained after or prior to affinity selection. The absorption step itself is an affinity selection step on a target expected not to bear the epitopes of interest. The target used for absorption/selection may be tissue sections,  
20    cell lines, recombinant proteins, peptides etc.

### Examples

**[0034]** The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for the illustration of  
25    certain aspects and embodiments of the present invention and are not intended to limit the invention.

### I. Materials and Methods

**[0035]** Except ~~[were]~~ where indicated otherwise, recombinant DNA methods and  
30    microbiological techniques were carried out using standard procedures such as described for example by Sambrook, J. et al. Molecular Cloning: A Laboratory Manual, Cold Spring harbor Laboratory Press, Cold Spring Harbor, NY (1989) and Ausubel, F.M. et al. Current

Protocols in Molecular Biology, John Wiley and Sons, Inc. (1995). Specific protocols for propagation and selection of phage antibodies are described in de Kruif, J., et al. Methods in Molecular Biology [~~(1996?)~~] (1996).

5 Construction of a synthetic phage antibody display library

[0036] The synthetic antibody library was constructed essentially as described (de Kruif et al., J. Mol. Biol. 248, 97 (1995)). Briefly, degenerate oligonucleotides were used to add synthetic CDR3 regions to a collection of 49 previously cloned germline VH genes. Subsequently, these [~~in-vitro~~] *in vitro* 'rearranged' VH genes were cloned into a collection of  
10 pHEN1 phagemid-derived vectors containing 7 different light chain V regions, fused in frame to the gene encoding the phage minor capsid protein geneIII. Introduction of these constructs into bacteria results, in the presence of helper phage, in the expression of scFv antibody fragments as geneIII fusion proteins on the surface of bacteriophage.

15 Preparation of tissue sections

[0037] Fixation, freezing, embedding and sectioning of tissues were carried out using standard procedures such as for example described in Zeller, R. in Current Protocols in Molecular Biology, pp 14.1.1-14.1.8, Ausubel, F.M. et al. Eds, Green Publishing and Wiley Interscience, New York. Immunohistochemical and immunofluorescent procedures were  
20 carried out using standard protocols such as for example described in Current Protocols in Immunology, pp 5.8.1-5.8.8, Coligan, J.E., et al. Eds. Wiley Interscience, New York.

Example I: selection using pepscan

Pepscan synthesis of CD64 peptides

25 [0038] Pepscan synthesis was carried out essentially as described (Geysen, H.M., et al, Proc. Natl. Acad. Sci. USA, 81, 3998 (1984)). In the exemplary embodiment, the extracellular domain of the CD64 molecule was synthesized on 25 polyethylene rods as adjacent, non-overlapping sets of 12-mer peptides, according to the scheme in Table I. Peptide-specific phages were isolated by affinity binding to the CD64 peptide-covered rods.  
30 The rods were blocked by incubation for two hours at room [~~tempertaure~~] temperature by placing the pepscan block for two hours at [~~roomtemperature~~] room temperature in wells of a 96-well microtiter plate containing 300 microliter 1x blocking buffer per well (2x blocking

buffer: 10% ovalbumin/10% horse serum/1% Tween-80 in PBS). The phages were were mixed 1:1 (v/v) with 2x blocking buffer and incubated for 30 minutes at room temperature. 250 microliter of the blocked phage solution containing approximately  $10^{12}$  phages were added per well of a 96 well plate and the 25 rods of the pepsan block were submerged in individual wells and incubated for 3 hours at ~~[room temperature]~~ room temperature. Non-specific phage antibodies were then removed by washing the rods 10 times in PBS/0.5% Tween-80 and one final time in PBS. Phage antibodies bound to the rods were then eluted by adding 300 microliter of 0.1M diethylamine buffer to each well of a microtiter plate and incubation for 5 minutes at ~~[room temperature]~~ room temperature. After collection of the 300 microliter, the elution step was repeated. To 600 microliter of eluted phages, 300 microliter of 1M Tris buffer pH 7.4 was added for neutralization. The 900 microliter eluted phage suspension was added to 4 ml 2TY containing 5% glucose and 10 microgram/ml tetracycline. Finally, 5 ml XL-1 blue cells (OD600 of 0.5) were added and the mixture incubated for 30 minutes at 37°C. The cells were centrifuged for 30 minutes at 3000 rpm, the supernatant removed by aspiration and the cells resuspended in 500 microliter of the remaining medium on two TYE plates containing 5% glucose, 100 microgram/ml ampicillin, 10 microgram/ml tetracycline and 5% glucose and the bacteria grown overnight at 37°C. The colonies were scraped from the bacterial plates and used to rescue phage antibody particles as described (de Kruif, J., et al., J. Mol. Biol. 248, 97 (1995)). From the resulting library enriched for peptide-binding phage antibodies,  $10^{12}$  phage antibodies in blocking buffer were incubated with the same peptide-covered rods and subjected to subsequent rounds of selection using the same procedure.

#### Cleaning of pepsan blocks

[0039] Blocks used for ELISA or phage selections were cleaned by submerging the ~~[pep sear]~~ pepsan blocks in ~~[disruptbuffer (phosphate buffer/1% SDS/0.1% beta-mercapto-ethanol, pH 7.2)]~~ disruption buffer (phosphate buffer/1% SDS/0.1% beta-mercapto-ethanol, pH 7.2) and placing the block in an ultrasonic waterbath at 70°C for 1 hour.

#### Analysis of selected phages in ELISA

[0040] After selection, preparations of monoclonal or polyclonal scFv antibodies were analyzed for the presence of peptide binding in ELISA using the same pepsan blocks used for selections. ScFv preparations instead of phage preparations were used because the latter generated a high background in ELISA. All incubations are carried out in 96-well microtiter plates. The cleaned rods were soaked in 300 microliter PBS for 30 minutes at [roomtemperature] room temperature and pre-coated by incubating each pin for 3 hours at [roomtemperature] room temperature with 150 microliter of blocking buffer (5% ovalbumin/5% horse serum/1% Tween-80, filtered over Whatman 41 paper). The rods were rinsed twice with PBS/0.05% Tween-80 and incubated for 1 hour at [roomtemperature] room temperature with 150 microliter scFv-containing periplasmic preparations prepared as described in de Kruif et al, J. Biol. Chem. 271, 7630 (1996)) mixed with 150 microliter blocking buffer. The rods were washed twice with PBS/0.05% Tween-80 and incubated for 1 hour with 300 microliter culture supernatant of a hybridoma secreting the anti-Myc tag antibody 9E10 (de Kruif, J., et al, J. Biol. Chem. 271, 7630 (1996)). The rods were washed twice with PBS/0.05% Tween-80 and incubated for 1 hour with 300 microliter of rabbit anti-mouse immunoglobulins conjugated to peroxidase, diluted 1:500 in PBS/0.05% Tween-80/1% BSA.

[0041] Finally, the rods were washed thrice with PBS/0.05% Tween-80 and incubated with ABTS substrate. A representative result of an anti-peptide scFv antibody, affinity-selected after three rounds for binding to peptide #21 on the CD64 block is shown in figure 2. This scFv antibody specifically bound to peptide #21 used as target for selection but not to other peptide-covered rods in the CD64 pepsan block (figure 2).

#### Selection and analysis of pepsan pre-selected phage antibodies by cell sorting.

[0042] Phage populations enriched for binding to peptides on the pepsan block may in the second or subsequent rounds be selected for binding to prokaryotic or eukaryotic cells expressing the target protein employing flow cytometry and cell sorting. The procedure for phage selection on intact cells using this procedure has been described in detail (de Kruif, J., et al. Proc. Natl. Acad. Sci. USA, 92, 3938). Approximately  $10^{13}$  phage antibody particles are blocked for 15 minutes in 4 ml 4% [~~milk powder~~] milk powder in PBS (MPBS).  $5 \times 10^6$  target cells were added to the blocked phages and the mixture was slowly rotated overnight at 4°C. The following day, cells were washed twice in 50 ml ice-cold PBS/1% BSA. The

pelleted cells were resuspended in 2 ml of ice-cold PBS/1% BSA for cell sorting or stained with fluorochrome-labeled monoclonal ~~[antibodies]~~ antibodies for sorting of a subpopulation of cells. To that end, 25 microliter of fluorochrome-labeled antibodies is added to the pelleted cells and after a 20 minute incubation on ice, cells were washed once  
5 with 1% BSA/PBS and resuspended in 2 ml ice-cold PBS/1% BSA. Cell sorting was performed on a FACSvantage.

[0043] The procedure for flow cytometric analysis of selected phage antibodies has been described in detail elsewhere (de Kruif, J., et al. Proc. Natl. Acad. Sci. USA, 92, 3938). For staining of cells, 100 µl monoclonal phage antibody containing approximately  $10^{11}$  particles  
10 was blocked by adding 50 µl 4% MPBS for 15 minutes at ~~[roomtemperature]~~ room temperature.  $5 \times 10^5$  leucocytes in 50 µl PBS/1% BSA were added and incubated on ice for 1 hour. The cells were washed twice in ice-cold PBS/1% BSA. To detect cell-bound phages, the cells were incubated in 10 µl of 1/200 diluted sheep anti-M13 polyclonal antibody (Pharmacia, Uppsala, Sweden), washed twice and incubated in 10 µl of 20 µg/ml PE-labeled  
15 donkey anti-sheep polyclonal antibody (~~[Jackson Immuno-research, West Grove, PA]~~) (Jackson Immunoresearch, West Grove, PA), each for 20 minutes on ice.

Selection of pepscan pre-selected phage antibodies on whole tissues or tissue sections.

[0044] Tissue sections from target organs are prepared and fixed by standard methods. For example, tissues may be submerged in OCT embedding medium and gently frozen by dipping in liquid nitrogen for 1 minute. Using a cryostat, 10 micrometer frozen sections are prepared and collected on microscope slides. The sections are dried for 10 minutes at  
20 ~~[roomtemperature]~~ room temperature and fixed in 100% acetone for 5 seconds, followed by drying at ~~[roomtemperature]~~ room temperature. Before incubation with the phage library, the tissue sections are sealed with wax to prevent spreading of fluid and blocked by incubation with MPBS for 30 minutes at ~~[roomtemperature]~~ room temperature. After the blocking step, a total of  $10^{12}$  phages from a phage antibody library pre-selected for binding to peptides is blocked with MPBS in a volume of 100 microliter and added to the droplet of  
25 MPBS on the slide. The tissue sections are incubated overnight in a moist chamber at  $40^{\circ}\text{C}$   
30 to facilitate binding of phage antibodies.

[0045] The sections are rinsed with a total of 2 liter PBS/0.5% Tween-20 for 2 hours at ~~[roomtemperature]~~ room temperature with ten 200 ml changes of PBS/0.5% Tween-20. After rinsing, the phage antibodies are eluted by placing 300 microliter 76 mM citric acid buffer (pH 2.5) on the slide and incubation for 5 minutes at ~~[roomtemperature]~~ room temperature. [Add] 150 microliter of 1 M Tris-HCL buffer are added to the slide for neutralization and the ~~[suspensi-on]~~ suspension is brought in 3 ml 2 TY medium in a 15 ml tube. 3 ml of XL-1 blue bacteria is added to the tube and infection and production of phages are allowed to proceed as described in the standard protocol. After 2-3 rounds of selection, monoclonal phage antibodies are prepared for analysis.

#### Analysis of selected phage antibodies by immunohistochemistry

[0046] Binding of monoclonal phage antibodies to tissues was determined by immunohistological screening. To this end, 5  $\mu$ m frozen tissue sections were collected on gelatin coated microscope slides. Sections were then incubated with 50 microliter phage solutions containing  $10^{10}$  phage particles in a moist chamber for 30 min. Non-adherent phages were removed by vigorously rinsing the slides in M-PBS-Tw. Bound MoPhabs were visualized by incubation of the sections with a 1:50 diluted sheep anti-M13 peroxidase conjugate, followed by incubation with the substrate diaminobenzidine.

#### Construction and selection of bi-specific antibodies from collections of phage antibodies affinity selected on pepsan blocks.

[0047] Monoclonal phage antibodies selected for binding to the CD64 peptides may be pooled and recloned in display vectors permitting the display of bi-specific antibodies such as for example vectors for diabodies (Holliger, P. et al., Proc. Nat. Acad. Sci. USA, 90, 6444 (1993) or leucine zippered bi-specific antibodies (de Kruif, J., et al. J. Biol. Chem. 271, 7630 (1996).

[0048] In the exemplary embodiment, a phagemid vector was constructed that facilitates the *in vivo* bacterial expression and assembly of bispecific (scFv)<sub>2</sub> fragments as secreted molecules or g3p fusion proteins on the surface of bacteriophages. The Fos and Jun scFv leucine zipper constructs we described (de Kruif, J., et al. J. Biol. Chem. 271, 7630 (1996); figure 3, 1 and 2) are PCR amplified using primers M13R and PDIM3 (5'-TTT GCA TTC



AAG CTT TTA TTA GCC CGC ATA GTC AGG AAC ATC GTA TGG GTA TGC GGC  
AGC GCA ACC ACC (SEQ ID NO:3)). Primer PDIM3 replaces the Myc tag with a

haemagglutinin (HA) tag and adds a ~~stop codon~~ stop codon and a HindIII site to these  
fragments. PCR products are digested with HindIII and cloned into vector pHEN1

5 (Hoogenboom, H.R., et al., Nucleic Acid Res. 19, 4133 (1991)) containing a scFv gene  
fused to the complementary leucine zipper and a Myc tag. In the resulting constructs both  
scFv-zipper fragments are encoded by a single transcript. Two ribosome binding sites allow  
the proteins to be translated individually, the first scFv fragment fused to a Fos zipper  
domain and an HA tag, the second scFv to a Jun zipper and a Myc tag (Figure 3, 3). To  
10 determine the effect of the position of the scFv-zippers relative to the g3p protein, an  
additional construct was made in which the scFv-zipper fragments were reversed (Figure 3,  
4). In suppressor *E. coli* strains, an amber codon inserted between the Myc tag and gene 3  
permits the production of phage particles displaying a scFv fragment fused via a zipper  
region to gene 3. The second scFv will associate with the phage in the periplasmic space by  
15 ~~[heterodimerization]~~ heterodimerization of the Fos and Jun leucine zippers, thus creating a  
phage expressing a bispecific antibody on its surface. In non-suppressor strains, bispecific  
(scFv)<sub>2</sub> fragments linked by a Fos Jun leucine zipper will be assembled in the periplasmic  
space.

[0049] Expression of (scFv)<sub>2</sub> fragments in non-suppressor bacterial strain SF110-FA was  
20 monitored by SDS-PAGE followed by blotting to nitrocellulose and detection with Myc-  
tag- and HA tag-specific monoclonal antibodies (MoAbs) (Figure 4, lower panel). In  
reducing SDS-PAGE, constructs 3 and 4 show expression of HA and Myc tagged proteins  
of the predicted size. The expression level of Myc tagged scFv fragments obtained with  
constructs 3 and 4 is lower when compared to that obtained with constructs 1 and 2, perhaps  
25 as a result of the simultaneous expression of a second scFv in bacteria harboring the former  
constructs. In non-reducing SDS-PAGE, only proteins approximately twice the size of a  
scFv-zipper are visible in all lanes (Figure 4, upper panel). The anti HA-MoAb detects  
multiple bands, whereas the anti Myc-MoAb detects only one. One of the fragments  
visualized with the anti-HA MoAb migrates at the same position as the fragments visualized  
30 with the anti-Myc MoAb. We hypothesize that this band represents the bispecific antibody  
and that the other HA-tagged proteins are homodimers resulting from a higher expression  
level of the first scFv-zipper in these constructs.

[0050] Functionality of the (scFv)<sub>2</sub> fragments was analysed in an ELISA (Figure 5). Using both the Myc tag- and HA tag-specific [~~MoAbs~~] MoAbs for detection, specific binding of the (scFv)<sub>2</sub> fragments to both target antigens could be demonstrated. In a sandwich ELISA we show the (scFv)<sub>2</sub> fragments are truly bispecific in linking two different  
5 antigens.

[0051] Recombinant phage antibody particles were produced using constructs 1-4 and analysed in an ELISA (Figure 5). Phages from constructs 2 and 3, containing the Jun-zipper fused directly to gene-3 show some non-specific binding to irrelevant antigens. Phages produced using constructs 1 and 4, containing the Fos-zipper fused to gene 3 recognize their  
10 target antigens only.

[0052] To test the feasibility of selecting bispecific phage antibodies from a phage repertoire, bispecific phage particles from construct 4 were spiked in a 1:1000 ratio in an antibody phage display library and subjected to one round of selection in immunotubes coated with either IgG or DNP. The frequency of bispecific phages after selection was  
15 estimated by PCR on individual colonies using primers M13R and FOSCON (5'-CGC CAG GAT GAA CTC C (SEQ ID NO:4), situated in the Fos zipper). Frequencies of bispecific phages after selection were 0/32 (spiked library), 9/32 (selected on IgG) and 6/32 (selected on DNP). Calculated enrichment factors ( $\pm 250\times$ ) are comparable to those obtained using monospecific phage antibodies.

[0053] This vector permits the expression of bispecific antibodies that can be functionally expressed on phages using Fos and Jun leucine zippers. It is therefore possible to construct libraries of phages expressing two different scFv fragments and select the desired combinations from these. Furthermore, selected bispecific (scFv)<sub>2</sub> fragments can be produced in non-suppressor strains and purified using anti-Myc followed by anti-HA  
20 affinity columns.  
25

[0054] For the selection of bispecific antibodies from phage antibody collections pre-selected for binding to peptides on pepscan blocks, care is taken to restrict the number of selection rounds (usually 2-3) on the rod-bound peptides to ensure enrichment for binders but to prevent loss of diversity by overselection. The V gene pools encoding the phage  
30 antibodies enriched for binding to the peptides are recloned into the leucine-zipper constructs and bispecific phage antibodies binding to the target protein are selected by any of the afore-described methods. In addition, it may be envisaged that higher affinity

bispecific antibodies are directly isolated by performing phage selection with the aid of surface plasmon resonance (Jonsson, U., et al. Biotechniques, 11: 620 (1991).

#### Example 2: selection on sections

##### 5 Preparation of tissue sections

[0055] Tissue sections from target organs are prepared and fixed by standard methods.

For example, tissues may be embedded in an embedding compound such as OCT and gently frozen by dipping in liquid nitrogen for 1 minute. Using a cryostat, 10 micrometer frozen sections are prepared and collected on microscope slides. The sections are dried for 10 minutes at [~~room temperature~~] room temperature and fixed in 100% acetone for 5 seconds, followed by drying at room temperature.

[0056] Alternatively, tissues may be fixed by incubation for several hours in 4% freshly prepared paraformaldehyde solution, dehydrated by serial passage through increasing concentrations of ethanol and embedding in paraffin wax.

##### 15 Paraffin blocks are cut into 6-8 micrometer sections.

Instead of tissue sections, freshly isolated or cultured cells may be used and subjected to the same procedures.

#### Affinity selection of phages on tissue sections

20 [0057] The frozen tissue sections are briefly dried at room temperature. The paraffin-embedded tissue sections are placed at 60°C for 1 hour and deparaffinized by immersing in three changes of fresh xylene, 4 minutes each, followed by two changes of 100% ethanol, 2 minutes each. Tissue sections are rehydrated in solutions of decreasing concentrations of ethanol and finally water, and washed with PBS.

25 [0058] Before incubation with the phage library, the tissue sections are sealed with wax to prevent spreading of fluid over the object glass, and blocked by incubation with 1% non-fat [~~milk powder~~] milk powder in phosphate buffered saline (MPBS) for 30 minutes at [~~room temperature~~] room temperature. After the blocking step, a total of  $10^{13}$  phages from the synthetic phage antibody display library is blocked with MPBS in a volume of 300 microliter and added to the droplet of MPBS on the slide. The tissue sections are incubated overnight in a moist chamber at 40°C to facilitate binding of phage antibodies.

[0059] The sections are rinsed with a total of 2-liter PBS/0.5%

Tween-20 for 2 hours at [~~room temperature~~] room temperature with 10 200 ml changes of PBS/0.5% Tween-20. After rinsing, the phage antibodies are eluted by placing 300 microliter 76 mM citric acid buffer (pH 2.5) on the slide and incubation for 5 minutes at  
5 [~~room temperature~~] room temperature. 150 microliter of 1 M Tris-HCL buffer is added to the slide for [~~neutralization~~] neutralization and the suspension is brought in 3 ml 2 TY medium in a 15 ml tube. 3 ml of XL-1 blue bacteria are added to the tube and infection and production of phages are allowed to proceed as described in the standard protocol. After 2-3 rounds of selection, monoclonal phage antibodies are prepared for analysis by  
10 immunohistochemistry.

Analysis of selected phage antibodies by immunohistochemistry

[0060] Binding of monoclonal phage antibodies to tissues was determined by  
15 immunohistological screening. To this end, 5  $\mu$ m frozen tissue sections were collected on gelatin coated microscope slides. Sections were then incubated with 50 microliter phage solutions containing approximately  $10^{10}$  phage particles in a moist chamber for 30 min. Non-adherent phages were removed by vigorously rinsing the slides in MPBS-Tw. Bound  
20 phage antibodies were visualized by incubation of the sections with a 1:50 diluted sheep anti-M13 peroxidase conjugate, followed by incubation with diaminobenzidine substrate.

Absorption of selected phages antibodies for unwanted specificities

[0061] A collection of phage antibodies selected for binding to a tissue section may be absorbed for unwanted phage antibody specificities. After elution and neutralization of  
25 bound phage antibodies, a 4% (w/v) MPBS solution is added to the eluate to reach a 1% concentration of non-fat milk. The phage solution is subsequently [~~incubated~~] incubated with a tissue sections of for example another tissue or a different anatomical region of the same tissue. Non-binding phages are removed and propagated directly or incubated with another tissue section for another round of absorption. This absorption procedure may be  
30 repeated multiple times before the eventual non-binding phages are propagated in bacteria.

Isolation of specific phage antibodies from tissue sections using a micromanipulator.

[0062] Individual cells or small regions of tissue and binding phages may be scraped from tissue sections using a micromanipulator or similar device, essentially as described (Kupper, R., et al. EMBO J., 12 4955 (1993)). This procedure allows the isolation of phages that bind to particular anatomical structure or individual cells in a tissue section. For example, this procedure allows the isolation of endothelial of ~~[bloodves-sels]~~ blood vessels penetrating a tumor mass or allow the isolation of individual tumor cells. Once scraped from the tissue [section] section, the bound phages are eluted and propagated as described in the basic protocol.

[Legends to the figures] BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1.

[0063] General principle of affinity selection of genetic display packages by binding to peptides synthesized on the rods of a pepsan block.

Figure 2.

[0064] ELISA results of a phage antibody affinity selected for binding to peptide #21 on the CD64 pepsan block. No binding above background to other peptides on the block was observed.

Figure 3.

[0065] Starting material (1 and 2) and bispecific constructs (3 and 4). LacZ promoters (triangles), ribosome binding sites (circles) pelB leaders (P), Fos-zippers (F), Jun-zippers (J), Myc tag (M), HA tag (H) and stopcodons (arrows) are indicated. Closed boxes and hatched boxes represent different scFv specificities.

Figure 4.

[0066] SDS-PAGE / Western blotting analysis. Periplasmic preparations from expressed constructs 1-4 were run under non-reducing (top panel) and reducing (bottom panel) conditions. Proteins were visualized using an HA-tag specific MoAb (left lanes) and a Myc-

tag specific MoAb (right lanes) followed by a peroxidase- conjugated antibody.

Figure 5.

- [0067] ELISA analysis using construct 1-4 derived antibody fragments. In standard
- 5 ELISA's, (scFv)<sub>2</sub> fragments were allowed to bind to antigen coated wells and detected using anti-Myc and anti-HA MoAbs followed by a peroxidase-conjugated antibody. [~~Sandwich~~]
- Sandwich ELISA's using bispecific (scFv)<sub>2</sub> fragments were performed as described (de
- Kruif, J. et al. J. Biol. Chem. 271, 7630). In phage ELISA, phage antibodies were allowed to
- bind to antigen coated wells and developed using a peroxidase-conjugated anti-M13
- 10 antibody. Numbers represent absorbance values. Values three times higher than the background binding to milk-blocked wells are considered to be positive (gray boxes).

pin #	amino acid sequence	pin #	amino acid sequence
1	MWFLTLLWVP ( <u>SEQ ID NO:5</u> )	14	KTNISHNGTYHC ( <u>SEQ ID NO:18</u> )
2	VDGQVDTTKAVI ( <u>SEQ ID NO:6</u> )	15	SGMGKHRYTSAG ( <u>SEQ ID NO:19</u> )
3	SLQPPWVSVFQE ( <u>SEQ ID NO:7</u> )	16	ISVTVKELFPAP ( <u>SEQ ID NO:20</u> )
4	ETVTLHCEVLHL ( <u>SEQ ID NO:8</u> )	17	VLNASVTSPILLE ( <u>SEQ ID NO:21</u> )
5	PGSSSTQWFLNG ( <u>SEQ ID NO:9</u> )	18	GNLVTLSCETKL ( <u>SEQ ID NO:22</u> )
6	TATQTSTPSYRI ( <u>SEQ ID NO:10</u> )	19	LLQRPGLQLYFS ( <u>SEQ ID NO:23</u> )
7	TSASVNDSGEYR ( <u>SEQ ID NO:11</u> )	20	FYMGSKTLRGRN ( <u>SEQ ID NO:24</u> )
8	CQRGLSGRSDPI ( <u>SEQ ID NO:12</u> )	21	TSSEYQILTARR ( <u>SEQ ID NO:25</u> )
9	QLEIHRGWLXLQ ( <u>SEQ ID NO:13</u> )	22	EDSGLYQCEAAT ( <u>SEQ ID NO:26</u> )
10	VSSRVFTEGEPL ( <u>SEQ ID NO:14</u> )	23	EDGNVLKRSPLE ( <u>SEQ ID NO:27</u> )
11	ALRCHAWKDKLV ( <u>SEQ ID NO:15</u> )	24	ELQVLGLQLPTP ( <u>SEQ ID NO:28</u> )
12	YNVLYYRNGKAF ( <u>SEQ ID NO:16</u> )	25	VWFHVLFLAVG ( <u>SEQ ID NO:29</u> )
13	KFFHWNSNLTIL ( <u>SEQ ID NO:17</u> )		

Table 1. Sets of oligopeptides representing the extracellular domain of CD64.